Skip to main content
SpringerLink
Log in

Assessment of adherence and healthcare costs of insulin device (FlexPen®) versus conventional vial/syringe

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Diabetes is difficult to manage and treatment involves significant lifestyle adjustments. Unlike the traditional method of insulin administration via the vial and syringe method, insulin pens might be perceived as less cumbersome and have potential to significantly increase patient adherence.

Methods

Using “real world” data, we examined the differences in adherence and costs between diabetic patients using an insulin FlexPen® (Novo Nordisk Inc, Princeton, NJ, USA) and those using traditional vial and syringe administration. Using a retrospective analysis of health insurance claims data between the years 2003 and 2008, we examined patients in the FlexPen cohort and analog vial cohort. Propensity score matching was used to match these cohorts (n=532 in each) according to baseline characteristics.

Results

Adjusted mean medication possession ratio when switched to FlexPen improved by 22 percentage points versus 13 percentage points when continuing to use vials (P=0.001). Diabetes-related healthcare costs when switched to FlexPen versus continuing on to use vials ($3970 vs. $4838, respectively, P=0.9368) and total healthcare costs ($13,214 vs. $13,212, respectively, P=0.9473) were not statistically different.

Conclusion

Without significant addition to the cost, insulin administration with FlexPen is associated with an improved adherence among patients who switched from vial-based insulin administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gonder-Frederick L, Cox D, Ritterband L. Diabetes and behavioral medicine: the second decade. J Consult Clin Psychol. 2002;70:611–625.

    Article  PubMed  Google Scholar 

  2. Clarke P, Gray A, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747–1759.

    Article  CAS  PubMed  Google Scholar 

  3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596–615.

    Article  Google Scholar 

  4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053.

    Article  PubMed  Google Scholar 

  5. Burge M, Gamache L, Pai H, Segal A. Hypoglycemia and self-care in elderly patients with diabetes mellitus. In: Munshi MN, Lipsitz LA, eds. Geriatric Diabetes. New York, USA: Informa Healthcare; 2007:331–356.

    Google Scholar 

  6. Burkhart P, Dunbar-Jacob J. Adherence research in the pediatric and adolescent populations: a decade in review. In: Hayman LL, Mahon MM, Turner JR. Chronic Illness in Children: An Evidence-based Approach. New York, USA: Springer; 2002:199–229.

    Google Scholar 

  7. Hirsch I. Insulin analogues. N Engl J Med. 2005;352:174–183.

    Article  CAS  PubMed  Google Scholar 

  8. Oiknine R, Bernbaum M, Mooradian A. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs. 2005;65:325.

    Article  CAS  PubMed  Google Scholar 

  9. Molife C, Lee L, Shi L, Sawhney M, Lenox S. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther. 2009;11:529–538.

    Article  PubMed  Google Scholar 

  10. Lee W, Balu S, Cobden D, Joshi A, Pashos C. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28:1712–1725.

    Article  PubMed  Google Scholar 

  11. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006;9:377–385.

    Article  PubMed  Google Scholar 

  12. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. J Am Med Assoc. 2007;297:278.

    Article  CAS  Google Scholar 

  13. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.

    Article  CAS  PubMed  Google Scholar 

  14. Brixner D, McAdam-Marx C. Cost-effectiveness of insulin analogs. Am J Manag Care. 2008;14:766–775.

    PubMed  Google Scholar 

  15. Brunton S. Safety and effectiveness of modern insulin therapy. Current issues in the management of type 2 diabetes. ConsultantLive, July 2009. Available at: imaging.ubmmedica.com/consultantlive/supplements/0907Con_DiabetesSup_HR.pdf. Accessed: March 8, 2010.

  16. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Healthcare costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29:1294–1305.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Michigan and STATinMED Research, 218 N. Fourth Avenue, Suite 205, Ann Arbor, MI, 48104, USA

    Onur Baser

  2. Novo Nordisk Inc., 100 College Road West, Princeton, NJ, 08540, USA

    Jonathan Bouchard, Tony DeLuzio & Mark Aagren

  3. i3 Innovus, 12125 Technology Drive, Eden Prairie, MN, 55344, USA

    Henry Henk

Authors
  1. Onur Baser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Bouchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tony DeLuzio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Henry Henk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark Aagren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Aagren.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baser, O., Bouchard, J., DeLuzio, T. et al. Assessment of adherence and healthcare costs of insulin device (FlexPen®) versus conventional vial/syringe. Adv Therapy 27, 94–104 (2010). https://doi.org/10.1007/s12325-010-0009-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0009-6

Keywords

Search

Navigation